Well, based on the BUB case, 'priced in' would be a 40% increase in SP. I think that in itself is way more than what the specifics of the deal justify, but I'm not Mr Market, I'm just Mr Me.
However, relative to that, a 10% increase seems on par given that A2's FDA application is also confirmed as being under review. I was sceptical whether theyd actually move on that, but I'm less sceptical that it'll be granted by the FDA.
A2M Price at posting:
$4.77 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)